Moderna is set to expand its pipeline of messenger ribonucleic acid (mRNA)-based products with three new development programmes.
The programmes comprise mRNA vaccine candidates against varicella-zoster virus (VSV) to lower the rate of shingles, herpes simplex virus (HSV) and a new checkpoint cancer vaccine.
The latest development builds on the company’s experience with its Covid-19 vaccine, Spikevax.
Currently, the company has five vaccine candidates in the developmental stage for latent viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), HSV and VZV.
Read more at Pharmaceutical Technology.